These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 12747901

  • 1. Combined salmeterol and fluticasone for COPD.
    Vassiliou V.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract] [Full Text] [Related]

  • 2. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb 10; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 3. [New studies refute steroid opponents. COPD--after all a case for corticosteroids?].
    Calverley P.
    MMW Fortschr Med; 2003 Jun 12; 145(24):20. PubMed ID: 12866294
    [No Abstract] [Full Text] [Related]

  • 4. Combined salmeterol and fluticasone for COPD.
    Khamis RY, Rajakulasingam RK.
    Lancet; 2003 May 10; 361(9369):1652; author reply 1652-3. PubMed ID: 12747905
    [No Abstract] [Full Text] [Related]

  • 5. Combined salmeterol and fluticasone for COPD.
    Pakhale SS, Goldstein RS.
    Lancet; 2003 May 10; 361(9369):1652; author reply 1652-3. PubMed ID: 12747904
    [No Abstract] [Full Text] [Related]

  • 6. Fluticasone/salmeterol: labeling change.
    Prescrire Int; 2008 Dec 10; 17(98):229. PubMed ID: 19418648
    [Abstract] [Full Text] [Related]

  • 7. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr 10; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 8. COPD: don't use fluticasone + salmeterol. Patients treated with inhaled fluticasone for chronic obstructive pulmonary disease (COPD) are more prone to pneumonia.
    Prescrire Int; 2007 Dec 10; 16(92):257-8. PubMed ID: 18092426
    [No Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown CP, Knobil K.
    Clin Ther; 2005 May 10; 27(5):531-42. PubMed ID: 15978302
    [Abstract] [Full Text] [Related]

  • 10. Medications to modify lung function decline in chronic obstructive pulmonary disease: some hopeful signs.
    Suissa S.
    Am J Respir Crit Care Med; 2008 Aug 15; 178(4):322-3. PubMed ID: 18676961
    [No Abstract] [Full Text] [Related]

  • 11. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 15; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 12. Summaries for patients. Effect of treatment with fluticasone with and without salmeterol on airway inflammation and lung function in patients with chronic obstructive pulmonary disease: a randomized trial.
    Ann Intern Med; 2009 Oct 20; 151(8):I21. PubMed ID: 19841438
    [No Abstract] [Full Text] [Related]

  • 13. [Salmeterol + fluticasone in COPD. Complementary treatment principles hold true in the COPD management, too].
    MMW Fortschr Med; 2003 Nov 13; 145(46):47. PubMed ID: 14699834
    [No Abstract] [Full Text] [Related]

  • 14. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr 13; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 15. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P, Wencker M, Glaab T, Vogelmeier C.
    Am J Respir Crit Care Med; 2007 Jan 15; 175(2):144-9. PubMed ID: 17053207
    [Abstract] [Full Text] [Related]

  • 16. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM.
    Am J Respir Crit Care Med; 2008 Aug 15; 178(4):332-8. PubMed ID: 18511702
    [Abstract] [Full Text] [Related]

  • 17. The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD.
    Hanania NA, Kalberg C, Yates J, Emmett A, Horstman D, Knobil K.
    Pulm Pharmacol Ther; 2005 Aug 15; 18(1):19-22. PubMed ID: 15607123
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters.
    Terzano C, Petroianni A, Ricci A, Allegra L.
    Eur Rev Med Pharmacol Sci; 2005 Aug 15; 9(4):209-15. PubMed ID: 16128040
    [Abstract] [Full Text] [Related]

  • 19. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW.
    Lung; 2006 Aug 15; 184(4):217-22. PubMed ID: 17006748
    [Abstract] [Full Text] [Related]

  • 20. Prevention of death in COPD.
    Kupfer Y, Tessler S.
    N Engl J Med; 2007 May 24; 356(21):2212-3; author reply 2213-4. PubMed ID: 17526086
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.